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APCrotein complex that regulates the stability of hundreds of cellular proteins and
thus, it is implicated in virtually all cellular functions. Most of the time, to be recognized and processed by the
proteasome, a protein has to be linked to a chain of ubiquitin molecules. Cell proliferation, apoptosis,
angiogenesis and motility, processes with particular importance for carcinogenesis are regulated by the
ubiquitin-proteasome system (UPS). In colorectal epithelium, UPS plays a role in the regulation of the Wnt/β-
catenin/APC/TCF4 signaling which regulates proliferation of colorectal epithelial cells in the bottom of the
crypts and the inhibition of this proliferation as cells move towards colon villi tips. In most colorectal cancers
APC (Adenomatous Polyposis Coli) disabling mutations interfere with the ability of the proteasome to
degrade β-catenin leading to uninhibited cell proliferation. Other key molecules in colorectal carcinogenesis
such as p53, Smad4 and components of the k-ras pathways are also regulated by the UPS. In this review I
discuss the role of UPS in colorectal carcinogenesis and colorectal cancer prognosis and aspects of its
inhibition for therapeutic purposes.
© 2008 Elsevier B.V. All rights reserved.1. Introduction
The proteasome is a multiprotein cellular complex which mod-
ulates or degrades the majority of cellular proteins. It has been
discovered by Hershko, Ciechanover and Rose who have been
awarded the Chemistry Nobel prize in 2004 for this discovery. As a
regulator of a variety of protein substrates, the proteasome plays a role
in virtually every cellular function including processes of paramount
importance for carcinogenesis such as proliferation, apoptosis,
angiogenesis and motility/metastasis [1]. Due to its involvement in
these processes, proteasome function is a requirement for the survival
of normal and neoplastic cells and indeed during apoptosis protea-
some is inhibited [2,3]. In order to be recognized by the proteasome
and be processed, a protein substrate needs to be linked to a chain of
the 76 amino-acid protein ubiquitin [4]. Ubiquitin linkage is
completed in a series of three reactions carried out by different
enzymes called ubiquitin activating enzymes or E1, ubiquitin-
conjugating enzymes or E2 and ubiquitin ligases or E3, respectively.
The proteasome has three enzymatic activities, chymotryptic, tryptic
and glutamyl-peptidyl activity. The importance of each activity varies
depending on the substrate [5]. Protein ubiquitination is a reversible
process and there exist de-ubiquitinizing enzymes that catalyze
proteins de-ubiquitination preventing degradation [6]. The protea-
some itself possesses such activity which in this case serves thell rights reserved.function of recycling ubiquitin for further use and facilitating protein
substrate processing [4].
Colorectal carcinoma is one of the most common cancers and its
prevalence is greater in developed countries compared with countries
in development for reasons related to diet. Despite the introduction of
several new drugs for the treatment of colorectal cancer over the last
decade that have prolonged survival of advanced stage patients, the
disease, when metastatic, remains always lethal and new treatments
are urgently needed. Several lines of investigation are actively pursued
worldwide in this disease and one of them researching the role of the
ubiquitin-proteasome system in colorectal cancer will be the subject
of this review.
2. UPS in the regulation of proliferation and differentiation of
colonic epithelium
The Wnt signaling pathway is a signal transduction pathway with
particular importance in colorectal development and in the regulation
of proliferation and continuous renewal of the adult colorectal
epithelium [7,8]. Ligation of Wnt to the membrane receptor Frizzled
inhibits the assembly of the destruction complex that would lead to
proteasomal degradation of β-catenin, allowing the transcription
factor to enter the nucleus and begin, in co-operation with the
transcription factor TCF4 (T-cell Factor 4), transcription of target genes
that lead to proliferation and differentiation of the cell. Among β-
catenin/TCF4 targets are cyclin D, c-myc, akt kinase and transcription
factor AP-1 (Activating Protein-1) subunits c-jun and fra-1 [9–12].
Increased β-catenin activity is observed in the bottom of colonic
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colonic villi giving rise to differentiated colonic epithelium. Cells in the
villi tips display lower β-catenin activity while they express higher
levels of APC (Adenomatous Polyposis Coli), a key component of β-
catenin destruction complex [13]. β-catenin-dependent transcription
plays a role in development in many human tissues but the particular
importance of Wnt signaling in colorectal epithelium and carcinogen-
esis may be derived from the fact that another Wnt regulated
transcription factor, Hath1 (Human Atonal Homolog 1) has a restricted
expression in human lower gastro-intestinal tract [14]. Hath1 is a basic
helix–loop–helix transcription factor that promotes differentiation of
colorectal epithelial cells and mucin production by gastro-intestinal
goblet cells [15,16]. It is regulated by proteasomal degradation in a
reverse to β-catenin way [17]. Wnt signaling pushes the balance of
GSK3β (a kinase that participates in β-catenin phosphorylation in
order to become ubiquitinated subsequently) activity away from β-
catenin and towards phosphorylation of Hath1 which is then
ubiquitinated and degraded in the proteasome. Hath1 has been
found to be down-regulated in colorectal cell lines and colonic
neoplastic tissues in contrast to normal adult human colorectum
where it is abundantly expressed [14]. Thus, the UPS plays a critical
role in the availability of both transcription factors β-catenin and
Hath1 that direct two different transcription programs and regulate
proliferation and differentiation in colorectal epithelium.
3. Common lesions in colorectal pathogenesis and regulations by
the UPS
Many molecular lesions that lead to colorectal carcinogenesis have
been identiﬁed and at least two different pathways from normal
colonic epithelium to colorectal carcinoma have been proposed.
Mutations in APC are one of the primary events setting the transition
from normal epithelium to a pathologic lesion termed Aberrant Crypt
Focus (ACF), in a ﬁrst pathway of colorectal carcinogenesis. ACFs are
the ﬁrst pathologic lesions that can be microscopically seen and are
characterized by crypts with larger size than the normal ones, an
increased pericryptic space and a thicker layer of epithelium [18,19].
ACF transition to adenomas happens when an activating mutation to
the proto-oncogene K-ras is added. For adenoma to carcinoma
transformation, neutralization of the tumor suppressors p53 and
Smad4 (also known as DPC4 — Deleted in Pancreatic Cancer 4) isFig. 1. Simpliﬁed representations of three major pathways involved in colorectal carcinogene
signalling. (C) TGF-β pathway. Molecules which are proteasome substrates are representedtaking place usually by mutation of the one allele and loss of
heterozygosity of the remaining normal allele. This sequence of
molecular events is exempliﬁed by the hereditary syndrome Familial
Adenomatous Polyposis (FAP) and is also the sequence leading to
carcinogenesis in 85–90% of sporadic human colorectal cancers. APC is
the gene mutated in the germ line in families with FAP leading to the
formation of dozens or even hundreds of polyps throughout the colon
of the affected family members. In the majority of the remaining 10 to
15% of sporadic colorectal cancers a different sequence of molecular
events is the culprit. This is a sequence that is also taking place in a
hereditary syndrome, Hereditary Non-Polyposis Colorectal Cancer
(HNPCC) and is due to mutations in one of the genes involved in
mismatch repair (MMR), the process that detects and repairs a
misaligned base in the double helix of DNA. MMR genes MSH2, MLH1,
MSH6 and PMS2 are most frequently mutated, triggering micro-
satellite instability consisting of multiple DNA defects that are most
prominent in areas with long repeats of the same nucleotide (known
as microsatellites). These areas are more prone to sequence mistakes,
which, due to repair proteins defects, are not corrected. As these
mutations accumulate the regulatory mechanisms of the cells are
paralyzed leading to malignancy.
Many of the molecular lesions leading to colorectal carcinogenesis
are directly related to the ubiquitin-proteasome system. APC is part of
the complex that executes the phosphorylation of β-catenin in order
for this transcription factor to become ubiquitinated and be
recognized by the proteasome for degradation (Fig. 1A). Thus,
mutations of APC in FAP or the majority of sporadic colorectal cancers
allow stabilization of β-catenin which can enter the nucleus and
execute its transcription function, transcribing genes leading to cell
proliferation and inhibition of apoptosis.
Activating mutations of k-ras in colorectal cancer leads to the
activation of several transduction pathways that start from this
oncogene. Raf kinase activated by k-ras triggers the MAPK cascade
which leads to activation of transcription factors such as AP1 [20].
Components of this transcription factor such as c-jun and c-fos as
well as kinases of the cascade such as ERK3 are proteasome
substrates (Fig. 1B). PI3K kinase is also a target of activation by k-
ras and its activation leads to activation of the akt kinase. Akt is a
serine/threonine kinase with multiple targets such as mdm2 (a E3
ligase for p53), Bad (an anti-apoptotic member of the bcl-2 family),
caspase 9, mTOR, IKK, and GSK3β kinases and transcription factorsis and regulated by the UPS. (A) The Wnt/β-catenin/TCF4 pathway. (B) K-ras initiating
in star signs. Arrows denote activation, ⊥ signs denote inhibition.
Fig. 2. The regulation of the transcription factor HIF-1 in normoxic and hypoxic conditions. HIF-1 is composed of the HIF-1α subunit which is ubiquitinated and degraded in normoxic
conditions (A) and of HIF-1β subunit which is not subject to UPS regulation. In hypoxic conditions (B) that are often present in tumor masses HIF-1α is not degraded by the
proteasome and is entering the nucleus to transcribe its target genes such as VEGF, erythropoietin and genes encoding enzymes of the anaerobic metabolism. VHL, the E3 ligase
mediating HIF-1α ubiquitination is mutated in about 10% of colorectal cancers leading to deregulated HIF activity. HIF target gene VEGF signalling is already clinically targeted in
colorectal cancer with the use of the monoclonal antibody bevacizumab.
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and favors proliferation. Both akt and phosphatase PTEN, its inhibitor,
are proteasome substrates [22,23].
Smad4, a signal transducer of the TGFβ pathway is frequently
involved in the pathogenesis of colorectal cancer and is a proteasome
substrate [24] (Fig. 1C). The same holds true for another tumor
suppressormutated in colorectal cancer, p53. p53's related protein p73
and p53's co-factor ASPP/53BP2 are also proteasome substrates [25].
HIF-1α (Hypoxia Inducible Factor 1α) is a transcription factor
involved in angiogenesis and cell survival under hypoxic conditions
and is regulated by the proteasome. In normoxia UPS degrades HIF-1α
(Fig. 2). The E3 ligase promoting its ubiquitination for proteasomal
degradation, VHL (Von Hippel-Lindau) is genetically mutated in the
eponymous syndrome and frequently somatically mutated in renal
carcinoma. About 10% of colorectal carcinomas bear VHL mutations
and in some of these cases a parallel hyper-expression of HIF-1α was
detected by immunohistochemistry [26].
As evidenced from this discussion pathways involved in color-
ectal cancer are regulated by the proteasome in multiple levels and
with multiple ways. It is this multiplicity of inﬂuences, though, that
makes the ﬁnal result of proteasome manipulation difﬁcult to
predict. For example, proteasome inhibition will activate β-catenin
by preventing its degradation, a pro-carcinogenic effect, while it
would have opposing effects in the k-ras/PI3K/akt pathway due to
both akt and negative regulator PTEN being a proteasome substrate.
Nevertheless the ﬁnal result of multiple cellular dysfunctions from
proteasome deregulation or inhibition would be expected to be
homeostatic loss and cellular death which would be predicted to
become more prominent in cells already unstable such as the
neoplastic cells.
4. Effects of proteasome inhibitors on colorectal cancer in vitro
and in vivo
Given the importance of the proteasome on cell regulation
including the regulation of several neoplastic processes, many studies
have sought to investigate the effect of proteasome inhibitors on
colorectal cancer.Proteasome inhibitors have been shown to inhibit proliferation
and induce apoptosis in a variety of cell types. Hematologic cancer
derived cells are among the most sensitive to proteasome inhibition
[27]. Both multiple myeloma and lymphoma cells display inhibition
of their proliferation after exposure to proteasome inhibitors and
indeed bortezomib is already in clinical use in multiple myeloma
patients and in advanced development in lymphoma. Proteasome
inhibition also leads to inhibition of proliferation in a variety of solid
tumors such as breast, prostate, head and neck and colorectal in
vitro and in vivo [28–33]. The inhibitory effects of proteasome
inhibitors on cell proliferation have been attributed to diverse
mechanisms. Inhibition of anti-apoptotic transcription factor NF-κB
is a prominent mechanism proposed to explain the inhibitory effects
of proteasome inhibitors. NF-κB is positively regulated by the UPS
because its inhibitor IκB is a proteasome substrate and can be
ubiquitinated and degradated by an active UPS system. In addition,
NF-κB family members p100 and p105 are cleaved to their active
counterparts p52 and p50 respectively by the proteasome [34]. The
same E3 ubiquitin ligase, β-TrCP, functions in the ubiquitination of
IκB for complete proteasomal degradation and in the ubiquitination
of p100 and p105 for partial proteasomal cleavage and activation.
The ﬁnal result of both processes is NF-κB transcription activation.
This activation is of particular relevance in colorectal cancer where,
due to β-catenin activation, β-TrCP is up-regulated, being a β-
catenin transcriptional target [35]. Indeed NF-κB up-regulation is
observed during colorectal carcinogenesis and can be at least in part
due to proteasomal activity [36,37].
Another transcription factor, p53 that is important for apoptosis
and cell cycle arrest under stress conditions, is regulated by the
UPS and may mediate inhibitory effects of proteasome inhibitors.
p53 has been termed the guardian of the genome for its
paramount importance in inducing cell cycle arrest when DNA is
damaged in order to be repaired or apoptosis when the damage is
irreversible [38]. p53 is regulated by ubiquitination with the
mediation of several E3 ligases, the most prominent and ﬁrst
described being mdm2 (also referred as hdm2 in humans). Other
E3 ligases of p53 include COP1 [39], Pirh2 [40], ARF-BP1/Mule [41]
and hUREB (human Upstream Regulatory Element Binding protein
Fig. 3. Regulation of the cell cycle and apoptosis by the UPS is mediated by stabilization of CDK inhibitor p27 (A) and of bcl-2 family members Bik, Bid, Bax and Bad (B), respectively.
Other important regulators of these processes such as, for example p21, p53, caspases, Smac/Diablo and securin, are also proteasome substrates.
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ubiquitin ligase expressed in colorectal carcinoma cells and its
expression is inversely correlated with the expression of p53 [42].
Forced expression of the HECT domain of hUREB1 in these cells
destabilizes p53.
The cyclin dependent kinases (CDKs) inhibitor p21 is a transcrip-
tional target of p53 and is induced after treatment of colorectal cancer
cells with the proteasome inhibitors LLnL and lactacystin [43].
Furthermore, p21 is a target of proteasome degradation and thus
proteasome inhibition directly stabilizes this cell cycle inhibiting
protein [44]. CDK inhibitor p27KIP1 is also a proteasome substrate and
mutations in residues that prevent its ability to be ubiquitinated for
proteasomal degradation decrease progression of intestinal polyps to
carcinomas in mice [45]. E3 ligase SCFSkp2 mediates p27 degradation
(Fig. 3). p27 levels do not play a role in tumor initiation but rather in
tumor progression, given the fact that polyp formation is not affected
by inhibition of p27 degradation in these mice. Moreover the reverse
is true and p27 reduction is associated with colorectal tumor
progression in APC mutant mice [46]. The underlying molecular
lesions that lead to tumor initiation may inﬂuence p27 ability to
inhibit tumor progression because in contrast to what happens in APC
mutant mice, in Smad3 mutant mice, p27 levels are not reduced with
tumor progression [46].
Several members of the bcl-2 regulators of apoptosis are
proteasome substrates (Fig. 3). Bik/NBK, a BH3-only pro-apoptotic
member of the family is induced after treatment of several colon
cancer cell lines with the proteasome inhibitors bortezomib and
MG132 [47,48]. This treatment-induced Bik/NBK accumulation led
to cell apoptosis which was reduced when cells were pre-treated
with Bik/NBK siRNA [47]. Pro-apoptotic bcl-2 family members Bax
and Bak are also up-regulated by treatment of HCT116 colorectal
cancer cells with bortezomib [49] while anti-apoptotic members
bcl-2 and bcl-xl are not affected [47,49]. It is worth mentioning
that the same effect of pro-apoptotic bcl-2 members stabilization
after proteasome inhibition has been observed in other cell types
[50–52] and may be a universal anti-neoplastic mechanism of
proteasome inhibition.
5. Proteasome inhibitors in combination with other agents in
colorectal carcinoma
Proteasome inhibitors have been tested in colorectal cancer in
combination with chemotherapeutic and other agents in order to
augment their tumor inhibiting effects through reversal of drug
resistance or additive cytotoxicity with different mechanisms.Topoisomerase II is an enzyme involved in DNA replication and
repair and is inhibited by chemotherapeutic agents such as etoposide
and the anthracyclines. Topoisomerase II inhibitor resistance is
mediated by a down-regulation of the enzyme by proteasome
degradation in stress conditions such as glucose deprivation or
hypoxia. This is relevant for the tumor environment in vivo because
in many tumors extensive areas are hypoxic and nutrient starved, and
thus would be expected to display topoisomerase II down-regulation.
Inhibition of the proteasome by lactacystin sensitizes HT29 colorectal
cancer cell line to topoisomerase II inhibitors etoposide and
doxorubicin in vitro [53]. Moreover lactacystin partially reverses
resistance of HT29 xenografts to etoposide in Balb/c-nude mice in
vivo. Reversal of topoisomerase II resistance by proteasome inhibitors
is not restricted to colorectal carcinoma. The cell line of ovarian origin
A2780 displayed reversal of etoposide resistance when co-treated
with lactacystin in glucose starvation conditions [53].
A similar phenomenon is seen with topoisomerase I inhibitor
camptothecin which induces proteasome-dependent down-regula-
tion of topoisomerase I in a variety of cell lines (among which
colorectal cancer cell lines) that results in resistance to the anti-
proliferative actions of the drug. Treatment with the proteasome
inhibitor MG132 reverses this resistance by stabilizing topoisomerase
I [54]. Additionally inhibition of the proteasome with bortezomib
prevented induction of the anti-apoptotic transcription factor NF-κB
that results from cell treatment with the topoisomerase I inhibitor
CPT-11 [55]. Combined treatment of colorectal cancer cell lines and of
colorectal xenograft bearing mice with bortezomib and CPT-11 or its
active metabolite, SN-38 resulted in signiﬁcantly enhanced inhibitory
activity compared with each drug alone [55].
Combination of proteasome inhibitors lactacystin and bortezomib
with cyclooxygenase (Cox) inhibitor sulindac enhances the cytotoxi-
city of each drug alone in vitro and in vivo in nude mice bearing
colorectal tumor xenografts [56,57]. These synergistic effects may
relate to the fact that Cox inhibitors prevent increased Cox-2 activity
resulting from proteasome inhibition-induced up-regulation of Cox-2
[58]. They are, though, at least partially Cox-independent because
synergy has been observed in colorectal carcinoma cells not display-
ing Cox activity [32,56].
Proteasome inhibitors bortezomib and PSI (N-benzyloxycarbonyl-
Ile-Glu(O-tert-butyl-Ala-leucinal) have been found to have synergistic
inhibitory effects with histone deacetylase inhibitors FK228 and CBHA
(m-carboxycinnamic acid bis-hydroxamide) in colorectal cancer cells
in vitro [59]. Generation of reactive oxygen species and stabilization of
the pro-apoptotic bcl-2 family member Bim may at least partially
mediate the synergistic effect.
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diverse agents not being classic UPS inhibitors
Diverse pharmacologic, dietary and other agents have been des-
cribed to have anti-neoplastic effects in colon that may be mediated
through proteasome inhibition.
Non-steroidal anti-inﬂammatory drugs (NSAIDs) are a class of Cox
inhibiting agents used clinically as analgesic and anti-inﬂammatory
drugs. They also possess anti-neoplastic properties which are to a
signiﬁcant extent Cox inhibition-independent [60]. In colorectal
cancer Cox inhibitors have chemo-preventive actions established
from epidemiologic studies [61–63] in addition to their tumor
suppressive and anti-neoplastic properties [64,65]. Anti-neoplastic
actions of NSAIDs in colorectal cancer are evident in both Cox
expressing and non-expressing cells and diverse mechanisms have
been proposed to explain this Cox-independent anti-cancer activity
such as direct IKK-β inhibition [66], spermidine/spermine acyl-
transferase (SSAT) induction [67,68], Peroxisome Proliferator Acti-
vated Receptor γ (PPARγ) activation [69] and reduction of β-catenin
transcriptional activity [70]. Proteasome inhibition is an additional
mechanism that has been found to play a role in aspirin induced
apoptosis [71]. Proteasome inhibition resulted in stabilization of
proteasome substrates such as Bax, IκB-α, p53 and p27. This inhibition
by aspirin was dose dependent and the most signiﬁcant effects were
seen with doses at or above 10 mM which are the levels where Cox-
independent proliferation inhibition is generally observed and which
are not easily attainable in the clinical setting, at least for prolonged
times. Other previously described Cox-independent effects of NSAIDs
in colorectal cancer may be proteasome inhibition-dependent. For
example the aforementioned reduction of β-catenin transcriptional
activity is accompanied by an accumulation of phosphorylated β-
catenin in cells [70], the form that would normally be processed for
ubiquitination and proteasome degradation.
Butyrate is a short chain fatty acid that is among the fatty acids
produced in the intestine by the bacterial metabolism of dietary
ﬁber. Fiber protects against colorectal neoplasia and this effect may
be mediated by butyrate which induces cancer cell apoptosis [72–
74]. Butyrate has been shown to inhibit proteasome activity and
inhibit NF-κB transcription activity through IκB-α stabilization [75].
Probiotics, non-pathogenic bacteria of the intestine also inhibit the
proteasome [76]. Such a probiotic combination called VSL#3 and
composed of Streptococcus thermophilus as well as lactobacillus and
biﬁdobacteria species inhibits proteasome activity of mouse colonic
cells in vitro, stabilizes IκB-α and as a result inhibits NF-κB and
decreases the production of MCP-1 (Monocyte Chemoattractant
Protein 1), a transcription target of NF-κB and mediator of inﬂam-
mation. In this manner probiotics have beneﬁcial effects in
conditions such as inﬂammatory bowel disease, infective and
antibiotic-associated diarrhea [77] and pouchitis [78]. By suppressing
inﬂammation in a generally pro-inﬂammatory environment and
through production of butyrate and other short chain fatty acids or
possibly additional means of inhibiting the proteasome, probiotics
help maintaining the good health of colon and prevent neoplasia
which is promoted by inﬂammation.
7. UPS components and substrates as prognostic indicators in
colorectal cancer
Given the important role of UPS in many processes related to
colorectal carcinogenesis, it comes as no surprise that several
components of the system as well as protein substrates are
differentially expressed in individual colorectal cancer cases with
differing aggressiveness and provide prognostic information.
β-TrCP (beta-Transducin repeat-Containing Protein) is an E3 ligase
that is involved in the proteasomal degradation of β-catenin and in the
partial cleavage of the NF-κB family precursor proteins p105 and p100to yield their active counterparts p50 and p52 respectively [34,79,80].
Moreover β-TrCP is a target gene of β-catenin/TCF4 transcription and,
as a result, is up-regulated in colorectal cancer where β-catenin is
activated due to APC mutations and disabling of the proteasomal
degradation machinery. Indeed a study has shown that increased β-
TrCP levels were associated with β-catenin activation, nuclear NF-κB
activity and decreased apoptosis in colorectal cancer cells [81]. In
addition tumors from patients withmetastatic stage disease displayed
higher levels of β-TrCP mRNA compared to tumors from patients
without metastases, witnessing for a role of β-TrCP-involved path-
ways in the aggressiveness of colorectal cancer [81].
Another member of an E3 ubiquitin ligase complex that has been
associated with prognosis in colorectal carcinoma is skp2 (S phase
kinase protein 2). Skp2 together with a regulator protein Cks1 (Cyclin-
dependent kinase subunit 1) are effecting the ubiquitination of Cdk
inhibitor p27KIP1. Over-expression of the two proteins has been
observed in patients with poor prognosis colorectal carcinoma [82].
Skp2 and Cks1 are strongly correlated with overall survival of patients
with colorectal cancer independently of grade and stage. A very
interesting ﬁnding in this study was that patients with advanced stage
colorectal carcinoma but a high Skp2 expression had better overall
survival than patients with early (stages I and II) disease but low Skp2
expression in immunohistochemistry [82]. This result illustrates
eloquently the paramount importance of the molecular making of a
tumor and speciﬁcally of UPS beyond gross pathologic extent in
colorectal carcinogenesis. Whether p27 is the only ubiquitination
target of Skp2 and Cks1 that deﬁnes the importance of the two
proteins in the prognosis of colorectal cancer is not known. Skp2 has
been implicated in the ubiquitination and degradation of CDK inhi-
bitor p21 which may also play a role in colorectal cancer pathogenesis
[83,84]. Nevertheless, the role of p27 is well established and several
studies describe the effect of its expression in the aggressiveness of
colorectal carcinoma [85,86]. Patients with all stages of colorectal
cancer whose tumors expressed p27 by immunohistochemistry had a
median survival of over 10 years while those patients with tumors not
expressing p27 had a median survival of less than 6 years [85].
Speciﬁcally for patients with stage II disease, the median survival was
greater than 219 months in patients with tumors having more than
50% p27 positive cells comparedwith amedian survival of 140months
in patients with tumors with less than 50% p27 positive cells and
69 months in patients with no p27 expression at all [85]. p27
expression in these patients with colorectal cancer was modulated by
differential proteasomal degradation and not by different degrees of
mRNA production. Extracts from tumors expressing different p27
levels were able to degrade recombinant puriﬁed p27 in different
degrees when incubated ex vivo, mimicking the in vivo situation. In a
series of 86 patients with early stage colorectal cancer undergoing
surgery for the primary tumor with a curative intent, from the 48
patient with more than 20% p27 staining in their tumor by
immunohistochemistry, 47 remained free from recurrence while
from 38 patients with less than 20% p27 positive cells 21 patients
had tumor recurrence [87]. In another study of 89 stage Duke A to C
colorectal cancer patients, using a 50% positivity for p27 as the cut-off
point, patients with high expression displayed a statistically sig-
niﬁcant better cancer-speciﬁc mortality [88]. In patients with
metachronous metastases from colorectal cancer, p27 was found to
be down-regulated in the metastatic tumor cells compared with the
primary tumors, a phenomenon not seen in metastatic colorectal
disease diagnosed at the same time (synchronous) with the primary
tumors, where p27 expressionwas low in both primary andmetastatic
sites [86]. p27 down-regulation in metachronous colorectal metas-
tases was due to increased protein degradation given that mRNA
expression by in situ hybridization remained unchanged, speaking for
the role of UPS in this protein degradation. The level of p27 during the
different phases of the cell cycle in normal tissues is not regulated in
the transcription level, as its mRNA levels remain stable throughout
Table 1
Clinical studies of bortezomib monotherapy or in combination with chemotherapeutic
agents that included patients with colorectal cancer
Agent(s) combined Phase Total pts. CoCa pts. Response Reference
– II 19 19 3 (15.8%) SD [111]
– I 44 16 2 (12.5%) SD [114]
Irinotecan I 51 23 5 (21.7%) SD [115]
Gemcitabine I 31 3 – [116]
Docetaxel I 14 1 – [117]
Carboplatin+paclitaxel I 53 2 – [118]
CoCa: colorectal cancer, pts: patients, SD: stable disease.
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is effectuated by phosphorylation, ubiquitination and proteasomal
degradation [89,90]. It is this regulation that fails in colorectal cancer
due to skp2 and cks1 over-expression (and possibly additional
mechanisms) leading to decreased p27 stability and increasing
tumor aggressiveness [91].
p97 protein also known with the alternative names VCP (Valosin
Containing Protein) and cdc48 is an ATPase of the AAA family (ATPase
Associated with diverse cellular Activities) [92] and constitutes an
integral part of the proteasome forming an homohexameric ring [93].
p97 is able, through interactions with diverse partner proteins, to
recognize poly-ubiquitinated substrates for protein degradation and
plays important roles in endoplasmic reticulum-associated degrada-
tion (ERAD), mitotic spindle disassembly and post-mitotic membrane
fusion [93–97]. In colorectal carcinoma patients whose tumors
showed high p97 expression were found to have statistically
signiﬁcantly higher probability of distant metastases development
and lower disease-free and overall survival compared with patients
whose tumors showed low p97 expression by immunohistochemistry
[98]. In this series of 129 patients, p97 expression was classiﬁed as
high or low with the staining of normal colonic mucosa as the
reference point. p97 has been shown to be involved in the activation of
transcription factor NF-κB by taking part in the recognition of
ubiquitinated I-κBα for proteasomal degradation [99,100], an event
that may explain the association of its hyper-expression with color-
ectal cancer prognosis.
p21WAF1 is another CDK inhibitor and proteasome substrate and is
degraded by the proteasome through both ubiquitin-dependent and
independent pathways [101–104]. In colorectal cancer, several studies
investigated p21 expression correlation with prognosis. In a series of
192 colorectal cancer patients of all stages, absent or low (less than
10% of cells) p21 expression was statistically signiﬁcantly associated
with poorer disease-free and overall survival than high expressors in
univariate analysis, although this prognostic signiﬁcance was lost in
multivariate analysis [105]. In another series of 126 patients that used
50% as the cut-off point between p21 high and low expression cases, a
statistically signiﬁcant poorer survival of low p21 expressors was
maintained even in multivariate analysis [106]. Yet in another study
that included only rectal stages I to III cancer patients, low p21
expression was associated with higher recurrence rate and disease-
free survival [107]. Nevertheless, other investigators have not found
p21 expression to be correlated with clinical outcomes in colorectal
cancer [108,109]. This may be related to a more complex regulation of
p21 than p27 and the fact that p21 is regulated not only by
proteasomal degradation but also by transcription control. In fact it
is a transcriptional target of p53 (a proteasome substrate itself and
bearing inactivating mutations in many advanced colorectal cancer
cases) and indeed p21 mRNA has been found to be decreased in
colorectal cancer [110].
8. Clinical studies of UPS inhibition in colorectal cancer
Following encouraging in vitro and in vivo xenograft data of
proteasome inhibition in colorectal cancer [28], a phase II study of the
proteasome inhibitor bortezomib, the only currently clinically avail-
able proteasome inhibiting drug, was undertaken in patients with
metastatic colorectal cancer [111]. Nineteen patients who had
received one to three lines of chemotherapy were treated in this
study with an intravenous dose of 1.3 mg/m2 on days 1, 4, 8 and 11 of a
twenty one days cycle and sixteen were evaluable for response. No
objective responses were seen. Thirteen patients had progressive
disease and three patients had stable disease as their best response
(Table 1). The median time to progression was 5.1 weeks and the
6 month progression-free survival was 11.4%. As a result the study was
closed before the ﬁrst 19 planned patients were entered. Nevertheless,
this negative study leaves some open questions regarding the efﬁcacyof proteasome inhibition with the bortezomib doses used. In
accompanying correlative studies no changes in transcription factor
NF-κB or its inhibitor I-κB were observed in biopsies obtained from
liver metastases before and after treatment. Bortezomib 1.3 mg/m2
twice weekly as used in this study causes 65% proteasome inhibition
[112] while most clinical responses in other solid tumors were
observed with proteasome inhibition above 70% [113]. This level of
inhibition was obtained with doses of 1.6 mg/m2 twice weekly which
was the dose recommended for phase II studies in a previous phase I
studies [113]. Nevertheless in another phase I dose escalation study of
two different schedules (twice weekly two out of three weeks or four
out of six weeks) of bortezomib in solid tumors, which included 16
colorectal cancer patients, two patients with stable disease had
received doses of 0.5 mg/m2 and 0.9 mg/m2, doses that resulted in a
mean proteasome inhibition of 36% and 52% at 1 h respectively [114].
All other patients treated in this study had progressive disease. This
study also established that the twice weekly schedule two out of three
weeks was better tolerated than the twice weekly four out of six
weeks schedule and allowed better delivery of intended doses at the
scheduled time.
Despite the good rational and the encouraging pre-clinical data, it
becomes clear from the above phases I and II studies of bortezomib that
in colorectal cancer the maximal tolerated doses do not produce
signiﬁcant antitumor results. This may be related to both pharmaco-
dynamic parameters and to innate tumor resistance to single drugs
which is a clinical problemwith several anti-neoplastic agents and has
led to the development of the concept of combination cancer therapy.
Indeed combinations of bortezomib with other agents is the most
promising approach for further development of the drug in colorectal
cancer as well as in other solid malignancies and has begun to be
explored. Based on pre-clinical data of in vitro synergism of
pharmaceutical proteasome inhibitionwith topoisomerase I inhibitors
[54,55] (see also section on Proteasome inhibitors in combinationwith
other agents in colorectal carcinoma), a phase I dose escalation studyof
bortezomib with irinotecan has been undertaken in 51 patients with
advanced solid tumors [115]. Twenty three patients with colorectal
cancerwere included. Bortezomib dose of 1.3mg/m2 on days 1, 4, 8 and
11 plus irinotecan 125 mg/m2 on days 1 and 8 every three weeks were
found to be themaximal tolerated doses for the combination andwere
recommended for phase II studies. Thirty four patients were evaluable
for response. Noobjective responseswere obtained in the entire cohort
but 10 of 34 patients (29%) had stable disease for at least 6 weeks.
Among these 10 patients ﬁve colorectal cancer patients were included
(22%, 5 of 23 patients in an intention to treat analysis). This is an
impressive stability rate given that these patients were heavily pre-
treated (median of 3 prior chemotherapy regimens, range 0 to 7) and
some of them had previously received irinotecan.
Three other phase I studies combining bortezomib with gemcita-
bine, docetaxel or the combination of carboplatin and paclitaxel have
been published in full paper [116–118] and had included small
numbers of colorectal cancer patients (three, one and two patients
respectively). None of these patients had obtained any response (Table
1), a fact probably expected from the borderline activity of gemcita-
bine, taxanes and carboplatin in colorectal malignancies. A next step
806 I.A. Voutsadakis / Biochimica et Biophysica Acta 1782 (2008) 800–808for bortezomib development in colorectal cancer would be to
investigate its combination with an established drug in this disease
such as oxaliplatin, irinotecan or 5-ﬂuoro-uracil and its analogues in
less heavily pre-treated patients, possibly with the addition of a
targeted anti-VEGF or anti-EGFR therapy such as bevacizumab,
cetuximab or panitumumab which have no signiﬁcant over-lapping
toxicities. Another strategy would be the combination of bortezomib
and an established cytotoxic drugwith novel targeted therapies which
have given encouraging pre-clinical results with bortezomib in
colorectal cancer, such as Cox inhibitors [32,56,57,119] or deacetylase
inhibitors [59]. Other proteasome inhibitors, such as NPI-0052 [120] or
compounds targeting different components of UPS are in initial phases
of development [121]. A good targeting strategy could be ubiquitin
ligases which would have the advantage of being more speciﬁc for the
stabilization of proteins served by the speciﬁc E3 ligase blocked [122].
Selection of patients to be entered in UPS inhibitor studies based on
evidence of increased UPS activity (e.g. decreased p27 expression)
could be a fruitful strategy based on the model of K-ras mutation
screening before treatment of colorectal cancer patients with EGFR
inhibitors [123]. Successful development of UPS inhibitors will permit
patientswithmetastatic colorectal carcinomawho have already one of
the longest prospects of survival among solid tumor patients (20 to
24 months) to obtain further improvement in prognosis with a hope
for the ultimate goal of a cure for metastatic cancer.References
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